​

Aurinia Pharmaceuticals (AUPH) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

AUPH Stock Forecast

Aurinia Pharmaceuticals (AUPH) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $13.00, with a high of $13.00 and a low of $13.00. This represents a 59.71% increase from the last price of $8.14.

$5 $6 $7 $8 $9 $10 $11 $12 $13 High: $13 Avg: $13 Low: $13 Last Closed Price: $8.14

AUPH Stock Rating

Aurinia Pharmaceuticals stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

AUPH Forecast vs Benchmarks

TypeNameUpside
StockAurinia Pharmaceuticals59.71%
SectorHealthcare Stocks 25.20%
IndustryBiotech Stocks 63.35%

Price Target Trends

1M3M12M
# Anlaysts--2
Avg Price Target--$9.50
Last Closing Price$8.14$8.14$8.14
Upside/Downside--16.71%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Jan, 25331--7
Dec, 24331--7
Nov, 24341--8
Oct, 24341--8
Sep, 24341--8
Latest Price Target by Analysts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 06, 2024Ed ArceH.C. Wainwright$13.00$6.9188.13%59.71%
May 02, 2024Maury RaycroftJefferies$6.00$5.1017.65%-26.29%
Jan 04, 2023RBC Capital$11.00$5.9485.19%35.14%
Aug 09, 2022H.C. Wainwright$26.00$8.27214.39%219.41%
Aug 08, 2022Oppenheimer$13.00$8.3755.32%59.71%
May 05, 2022H.C. Wainwright$30.00$11.37163.85%268.55%
Apr 28, 2022RBC Capital$22.00$10.41111.34%170.27%
Latest Upgrade/Downgrade by Analysts
DateCompanyPrevious RatingNew RatingRating Change
Sep 06, 2024H.C. WainwrightBuyBuyhold
May 02, 2024JefferiesHoldHoldhold
Jan 04, 2023RBC CapitalOutperformOutperformhold
Aug 08, 2022OppenheimerOutperformOutperformhold
Apr 28, 2022RBC CapitalOutperformOutperformhold
Feb 23, 2022RBC CapitalOutperformOutperformhold
Dec 10, 2021OppenheimerOutperformupgrade

Financial Forecast

EPS Forecast

Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.87$-1.40$-0.76$-0.54-----
Avg Forecast$-0.90$-1.41$-0.84$-0.52$0.03$0.57$0.85$1.03$1.34
High Forecast$-0.96$-1.50$-0.91$-0.59$-0.03$0.47$0.68$0.77$1.20
Low Forecast$-0.83$-1.31$-0.76$-0.50$0.11$0.67$1.09$1.25$1.47
Surprise %-3.33%-0.71%-9.52%3.85%-----

Revenue Forecast

$0 $80M $160M $240M $320M $400M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$50.12M$45.60M$134.03M$158.53M-----
Avg Forecast$11.21M$43.86M$133.47M$176.00M$235.68M$274.40M$337.66M$335.00M$367.50M
High Forecast$10.56M$41.30M$124.35M$173.59M$232.69M$257.69M$333.95M$307.42M$337.25M
Low Forecast$11.75M$45.98M$141.74M$177.54M$238.77M$288.46M$341.36M$360.10M$395.04M
Surprise %347.11%3.98%0.42%-9.92%-----

Net Income Forecast

$-200M $-110M $-20M $70M $160M $250M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-102.68M$-180.97M$-108.18M$-78.02M-----
Avg Forecast$-110.20M$-162.18M$-136.63M$-78.02M$6.33M$86.16M$129.13M$144.49M$191.94M
High Forecast$-132.24M$-194.62M$-163.95M$-93.62M$-3.72M$67.03M$98.05M$109.74M$171.40M
Low Forecast$-88.16M$-129.75M$-109.30M$-62.42M$16.39M$95.34M$155.48M$179.23M$210.63M
Surprise %-6.82%11.58%-20.82%------

AUPH Forecast FAQ

Is Aurinia Pharmaceuticals stock a buy?

Aurinia Pharmaceuticals stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Aurinia Pharmaceuticals is a favorable investment for most analysts.

What is Aurinia Pharmaceuticals's price target?

Aurinia Pharmaceuticals's price target, set by 4 Wall Street analysts, averages $13 over the next 12 months. The price target range spans from $13 at the low end to $13 at the high end, suggesting a potential 59.71% change from the previous close price of $8.14.

How does Aurinia Pharmaceuticals stock forecast compare to the average forecast of its sector, industry, and investment themes?

Aurinia Pharmaceuticals stock forecast shows a 59.71% upside, outperforming the average forecast for the healthcare stocks sector (25.20%) and underperforming the biotech stocks industry (63.35%).

What is the breakdown of analyst ratings for Aurinia Pharmaceuticals over the past three months?

  • January 2025: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • December 2024: 42.86% Strong Buy, 42.86% Buy, 14.29% Hold, 0% Sell, 0% Strong Sell.
  • November 2024: 37.50% Strong Buy, 50.00% Buy, 12.50% Hold, 0% Sell, 0% Strong Sell.

What is Aurinia Pharmaceuticals’s EPS forecast?

Aurinia Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December is 0.03 for 2024, a -105.56% decrease from the reported $-0.54 in 2023. The prediction for 2025 is $0.57, $0.85 for 2026, $1.03 for 2027, and $1.34 for 2028.

What is Aurinia Pharmaceuticals’s revenue forecast?

Aurinia Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December is $235.68M for 2024, a 48.66% increase from the reported $158.53M in 2023. The forecast for 2025 is $274.4M, $337.66M for 2026, $335M for 2027, and $367.5M for 2028.

What is Aurinia Pharmaceuticals’s net income forecast?

For its fiscal year ending in December, Aurinia Pharmaceuticals's average annual net income forecast is $6.33M for 2024, reflecting a -108.11% decrease from the reported $-78.02M in 2023. The projection for 2025 is $86.16M, $129.13M for 2026, $144.49M for 2027, and $191.94M for 2028.